Breaking Presentation News Today

Use of a novel miniaturized, expandable percutaneous ventricular assist device was shown to be feasible and potentially safe in a small study of six high-risk patients undergoing PCI, a speaker reported.The first-in-human data of a novel percutaneous VAD system (Supira Medical) for high-risk PCI were presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.

Findings from a survey of operators who used a next-generation transcatheter aortic valve replacement system indicated improved deployment and commissural alignment vs. the device’s predecessor system, a speaker reported.The results of the next-generation self-expanding TAVR system (Evolut FX, Medtronic) limited market release clinical survey were presented at the Society for Cardiovascular

Pulmonary embolism treatment with a large-bore mechanical thrombectomy system was associated with favorable long-term outcomes, including low mortality and improved hemodynamics, functional capacity and quality of life, a speaker reported.The 6-month results from an analysis of the FLASH registry, a prospective analysis of a mechanical thrombectomy system (FlowTriever, Inari Medical), were

A virtual PCI road mapping tool could increase procedural safety vs. conventional angiography by reducing contrast volume and the number of angiograms necessary, a speaker reported.A real-world analysis of a roadmap tool (Dynamic Coronary Roadmap, Philips) for simple and complex PCI was presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.

Distal radial artery access for PCI showed no significant change in hand function and similar rates of access-site bleeding and radial artery occlusion at 1 year vs. proximal access, a speaker reported.The 1-year outcomes of the DIPRA trial were presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.

A novel 48-mm stent for the treatment of diffuse de novo coronary artery lesions was found to be safe and effective at 1 year, with a high level of device deliverability, a speaker reported.The results of the prospective, single-arm, open-label, multicenter global SPIRIT 48 trial were presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions and simultaneously

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation

Almirall: Lebrikizumab’s 52-week late-breaking data will be presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress The abstract entitled Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Co...